To improve clinical outcome in patients with lung cancer by undertaking large scale, novel lung cancer therapeutic trials including small molecules and angiogenesis inhibitors. Phase III trials examining the role of biological agents including thalidomide and erlotinib (Tarceva, OSI-774) in advanced lung cancer.